Introduction
Apoptosis is vital to all multicellular organisms for normal development and tissue homeostasis (Reed, 2000) . Proteases participate in the protein destruction and the regulation of protein activities in cellular context (Nagata, 1997; Reed, 2000) . As a type of protease, caspase plays a central role in the activation and propagation of death signaling (Nicholson, 1999; Kumar, 1999) . Functionally, the mammalian caspases could be classified into either initiator caspases or effector caspases. Along with caspase-9 and -10, caspase-8 is considered to be an initiation phase caspase. Upon activation of the death receptors such as Fas and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, the adaptor protein Fas-associated death domain protein (FADD) is recruited to the receptors, allowing subsequent binding of caspases-8 form the death-inducing signaling complex (DISC) (Nagata, 1997; Reed, 2000) . After caspase-8 is activated, it can process effector caspases, thereby activating a caspase cascade (Nicholson, 1999; Kumar, 1999) . Also, caspase-8 plays a role in the mitochondrial apoptotic pathway by cleaving the BH3-interacting death agonist (Bid), which can then promote the release of mitochondrial factors (Reed, 2000) .
Human cancers may arise as the result of an accumulation of mutations in genes and subsequent clonal selection of variant progeny with increasingly aggressive behaviors. Also, among the remarkable advances in our understanding in cancer biology is the realization that apoptosis has a profound effect on the malignant phenotypes (Hanahan and Weinberg, 2000) . Failure of apoptosis could allow the survival of transformed cells that are prone to undergo further genetic damage and play an important role in the pathogenesis of tumors. Apoptosis of cancer cells can be delayed or blocked by several ways, including somatic mutation, loss of expression of proapoptotic proteins and overexpression of apoptosis-inhibitory proteins. Somatic mutations of apoptosis-related genes, including the death receptors, Bcl-2 members and caspases, have been reported in human cancers, and many of the mutations were proven to inactivate cell death (McDonnell et al., 1989; Mandruzzato et al., 1997; Rampino et al., 1997; Lee et al., 1999; Takita et al., 2001; Liu et al., 2002; Shin et al., 2002; Soung et al., 2003; Kim et al., 2003) . Caspase-8 mutations have been reported in some cancer cell lines and colon cancer tissues (Mandruzzato et al., 1997; Takita et al., 2001; Liu et al., 2002; Kim et al., 2003) . However, to date, the data on the caspase-8 mutation is lacking in hepatocellular carcinoma (HCC) that occurs with a high incidence in Asia and is one of the leading cause of cancer death in the world (Bae et al., 2002) . In the present study, to explore the possibility that genetic alterations of caspase-8 gene might play a role in hepatocellular tumorigenesis, we analysed 69 HCCs and four accompanying preneoplastic lesions from dysplastic nodules (DN).
Results

Mutations and allelic status of caspase-8 gene in the HCCs
Through the microdissection technique, we selectively procured tumor cells from histological sections of the 69 HCCs as shown previously (Lee et al., 1998) . Genomic DNA was isolated and analysed for the potential mutations in the coding region and the exon-intron junctions of caspase-8 gene by polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis. Enrichment and DNA sequencing analysis of aberrantly migrating bands on the SSCP led to the identification of nine mutations in the 69 HCC tissues (13.0%) ( Figure 1 and Table 1 ). Of the four HCCs with DNs, one showed caspase-8 mutations both in the HCC and the low-grade dysplastic nodule (LGDN). None of the normal samples from the same patients showed evidence of mutations by SSCP (Figure 1 ), indicating the mutations had risen somatically.
Of note, all of the mutations were an identical two base-pair deletion mutation in the exon 7 (1225_1226delTG) in unrelated patients. This mutation would result in the frameshift of the caspase-8 aminoacid sequences within the codons 410-436 and result in a premature stop at the codon 437. The histologic grades (Edmondson grade), background lesions (cirrhosis or chronic active hepatitis) and types of hepatitis virus infection (Hepatitis B virus (HBV) or Hepatitis C virus (HCV)) were not significantly correlated with the caspase-8 mutation (Fisher's exact test, P>0.05). We repeated the experiments three times, including PCR, SSCP and sequencing analysis to ensure the specificity of the results, and found that the data were consistent (data not shown).
We examined the allelic status of caspase-8 in the tumors by using the three intragenic polymorphisms. Among the nine cases with the caspase-8 mutation, five were heterozygous for one or more polymorphism (s), and three (cases 58, 80 and 101) of them (60%) showed evidence of allelic loss ( Figure 1c ; Table 1 ). Importantly, in the case 101, the loss of heterozygosity (LOH) was observed both in the HCC and LGDN (Figure 1c ).
Reduction of apoptosis activities by the caspase-8 mutation
To determine whether the mutant form of caspase-8 is functionally defective, we generated caspase-8 expression vector containing the mutation found in the study. On transfection into 293T cells, we found that the 1225_1226delTG mutant showed a significant defect in cell death induction compared to the wild-type caspase-8 (Figure 2a ; ANOVA and Duncan's multiple range test, Po0.001). The cell death activity of the 1225_1226delTG mutant was comparable to a dominant-negative (D/N) caspase-8 mutant (an artificial caspase-8 C360A mutant that has a mutation at the activation site). Figure 2b also shows that the mutant expressed well and the levels of the expression were similar to that of the D/N caspase-8.
Also, to see whether the reduced cell death by the caspase-8 mutation was accompanied with the decreased cleavage of key proteins destructed during the cell death, we transfected the caspase-8 mutant or the wild-type caspase-8 in 293T cells, and compared their poly(ADPribose) polymerase (PARP) cleavages in the lysates by immunoblotting with anti-PARP antibody. The 1225_1226delTG mutant showed the absence of the Tissue expression of caspase-8
In addition to genetic alterations, epigenetic modification of caspase-8 by DNA methylation has recently been implied in loss of caspase-8 function in several solid tumors of childhood (Fulda et al., 2001; Takita et al., 2001) . To see whether caspase-8 expression is lost in the HCC, we performed caspase-8 immunohistochemistry in the 69 HCC samples. We observed that all of the HCCs as well as the cirrhosis showed detectable caspase-8 expression in the cytosol of the cells ( Figure 5 ). Negative controls using nonimmune serum as primary antibodies showed no signal (data not shown).
Discussion
Our previous observation that caspase-8 gene is mutated in colon cancers led us to analyse whether caspase-8 gene is mutated in other human cancers besides colon cancer. In the present study, we found that the HCCs harbored caspase-8 gene mutation as well, and that caspase-8 mutation could occur in the preneoplastic lesion of HCC. These data together with the data on the functional inactivation of caspase-8 activity by the mutation (Figures 2 and 3) suggest that caspase-8 mutation may be involved in the HCC pathogenesis, especially at the early stage of HCC development. Notably, all of the nine mutations detected in this study were an identical frameshift mutation that occurred in unrelated patients. This observation is quite contrast to the previous reports on apoptosis-related gene mutations, which showed that most of the mutations were missense mutations and were not an identical mutation (McDonnell et al., 1989; Mandruzzato et al., 1997; Rampino et al., 1997; Lee et al., 1999; Takita et al., 2001; Liu et al., 2002; Shin et al., 2002; Kim et al., 2003; Soung et al., 2003) . One possibility could be that our PCR-SSCP method was not able to detect mutations other than the 1225_1226delTG mutation. However, that possibility is unlikely because in the previous study we were able to detect other types of caspase-8 gene mutation besides 1225_1226delTG mutation in the colon cancers by the same PCR-SSCP methods . Another possibility could be that the recurrent mutations were due to artificial errors including contamination of the samples. This is also unlikely because we analysed other gene mutations, including phoshoinositide-3-kinase, catalytic alpha (PIK3CA) gene, in the same HCC tissues, and found that the nine HCC tissues with the 1225_1226delTG mutation did not show the same mutational pattern of PIK3CA gene (unpublished data by Lee JW and Lee SH). There is an example of recurrent somatic mutations of apoptosis-related gene. In transitional cell carcinomas of urinary bladder, Fas gene was mutated in cancer cells and eight out of 12 mutations were the same missense mutation (Lee et al., 1999) . Among the Fas, therefore, the 1225_1226delTG mutation in the caspase-8 gene may represent a mutational hotspot in the HCC. The 1225_1226delTG caspase-8 gene mutation would change the structure of the last 70 amino acids (amino acids 410-479) in the p10 subunit of wild-type caspase-8. As the active caspase-8 consists of a (p20/p10) 2 tetramer (Muzio et al., 1996) , the frameshift mutation may lead to abnormal construction of the tetramer and inhibit the protease function of caspase-8.
Chromosome 2q33-34, where caspase-8 gene resides, has been reported as a common deleted region in human cancers. In a previous report, LOH of chromosome 2q33-34 was observed in approximately 40% of the informative HCC cases (Li et al., 2001) . In agreement with this, the second allele of caspase-8 was lost in three of the five informative HCC cases with the caspase-8 mutation, indicating that caspase-8 mutation might be one of the responsible alterations for the LOH at 2q33-34 in the HCC.
Inactivation of caspase-8 function can also be occurred by the promoter DNA methylation in some malignancies (Fulda et al., 2001; Takita et al., 2001) . To see whether caspase-8 in HCCs could be inactivated by loss of protein expression, we analysed caspase-8 protein expression by immunohistochemistry. All of the HCC samples expressed caspase-8 protein (Figure 5 ), indicating caspase-8 in the HCCs may not be transcriptionally inactivated by DNA methylation and suggesting somatic mutation might be a main mechanism of caspase-8 inactivation in the HCC.
HCC progression is a stepwise process from preneoplastic lesions including LGDN and HGDN to advanced HCC (Maggioni et al., 2000) . However, the exact nature of this process is still unclear. The presence of the caspase-8 mutation in an LGDN suggested that caspase-8 mutation could be involved in the early event of HCC carcinogenesis. Also, interestingly, the second allele of losses of caspase-8 gene both in the HCC and the LGDN (Figure 1c ) of the same patient samples suggests that during the HCC carcinogenesis, both caspase-8 mutation and allelic loss may occur at the early stage.
A central aim of cancer research has been to identify the mutated genes that are causally implicated in tumorigenesis. Mutations in cancer could be categorized either functional alterations affecting key genes underlying the neoplastic process or nonfunctional 'passenger' changes. However, unfortunately, the prevalence of passenger mutations in the cancer genomes is not known. In general, high incidence of the mutation and functional derangements by the mutation may support the idea that the mutated gene is a cancer-related gene, but not a passenger gene (Futreal et al., 2004) . Relatively common incidence (13.0%) and inactivation of cell death function by the mutation suggest that the 1225_1226delTG mutation may be a functional alteration, but not a passenger alteration in HCC pathogenesis.
Caspase affects signaling pathways that might be amenable to therapeutic intervention in cancer cells. For example, small molecules as activators of caspases, which are sufficient for overcoming apoptosis suppression, could be used for treatment of cancer (Jiang et al., 2003) . It is well known that targeting the specific mutations in cancer cells by drugs such as Gleevec and Iressa has been identified as an effective approach to treat cancers (Downward, 2003; Lynch et al., 2004) . As in this study the HCCs harbored an identical caspase-8 mutation, possibly the 1225_1226delTG caspase-8 mutation could be a candidate therapeutic target for HCC. Although reactivation of the incapacitated caspase-8 is likely to be pharmacologic challenging, our data could provide useful data for the future antineoplastic intervention targeting the mutated apoptosis machineries.
Materials and methods
Patients and tissue samples
The HCC tissues were obtained from 69 patients who underwent surgical treatments for the HCC. The HCCs consisted of Edmondson grade I (n ¼ 8), grade II (n ¼ 30) and grade III (n ¼ 31), according to Edmondson and Steiner's (1954) criteria. Of the HCC tissues, two tissues included LGDN lesions and another two included high-grade dysplastic nodule (HGDN) lesions as well (International Working Party, 1995) . Ages of the patients ranged from 26 to 89 years with an average of 51.6 years. The background histology of the HCCs showed cirrhosis in 56 (81.1%) cases, chronic active hepatitis in 10 (14.5%) cases, chronic persistent hepatitis in two (2.9%) cases, and nonspecific changes in one (1.5%) case. HBV and HCV were detected in 62 (90.0%) and four (5.7%) cases, respectively. The tumor size of the patients ranged from 1 to 11 cm in diameter with an average of 5.7 cm. Approval was obtained from institutional review board of the Catholic University of Korea, College of Medicine. Informed consent was provided according to the Declaration of Helsinki.
Immediately after hepatectomy, the removed HCC tissues were snap-frozen in liquid nitrogen and stored at À801C until use. Malignant cells and normal cells were selectively procured from hematoxylin and eosin-stained frozen sections using a 301/2 gauge hypodermic needle (Becton Dickinson, Franklin Lakes, NJ, USA) affixed to a micromanipulator, as described previously (Lee et al., 1998) . DNA extraction was performed by a modified single-step DNA extraction method, as described previously (Lee et al., 1998) .
PCR-SSCP
Genomic DNAs from tumor cells and matched normal cells from the same patients were amplified with 14 primer pairs covering the entire coding region (eight exons) of human caspase-8b gene by PCR. Radioisotope ([ 32 P]dCTP) was incorporated into PCR products for the detection by autoradiography. The PCR products were loaded onto the SSCP gels. The procedures of PCR and SSCP analysis were performed as described previously (Lee et al., 1998) . After SSCP, bands showing mobility shifts were cut out from the dried gel, and re-amplified for 30 cycles using the same primer sets. Sequencing of the PCR products was carried out using the cyclic sequencing kit (Perkin-Elmer, Foster City, CA, USA).
To analyse the allelic status of caspase-8 gene in the tumors, we have used three intragenic polymorphisms (960 A/G, IVS9 -19A/G and 789 A/G) within caspase-8 gene. SSCP analysis at these polymorphic sites was used for the detection of LOH as well as for the detection of mutations. Complete or nearly complete absence of one allele in tumor DNA of informative cases, as defined by direct visualization, was considered as LOH.
Site-directed mutagenesis
The plasmid constructs encoding FADD and caspase-8 were described previously . Site-directed mutagenesis was performed using a Quick Change Site-Directed Mutagensis kit (Stratagene, La Jolla, CA, USA), according to the manufacturer's instructions. To change a base, a plasmid that contained the caspase-8b gene in pcDNA3.1 with Flag tag at the N-terminus was used as a template. The nucleotide sequences of the mutagenized plasmids were confirmed by DNA sequencing.
Transfection and cell death assay
Human embryonic kidney 293T cells in log phase were transfected in six-well plates with expression vectors together with 0.2 mg of green fluorescence protein (GFP) marker plasmid pEGFP N2 (CLONTECT, Palo Alto, CA, USA) using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). At 24 h after the transfection, the adherent and attached cells were pooled, fixed in 10% methanol for 15 min, and stained with 1 mg/ml 4 0 -6-diamidino-2-phenylindole (DAPI) for 15 min. The percentage of GFP-positive cells with nuclear apoptotic morphology was counted under fluorescent microscope (mean7s.d.: n ¼ 3).
Co-immunoprecipitations and immunoblotting assay
After transfection, cell lysates were subjected to immunoprecipitation using agarose-conjugated anti-Flag M2 antibodies (Sigma, St Louis, MO, USA). Immunocomplexes were fractionated by SDS-PAGE and transferred onto nitrocellulose membranes. The resulting blots were incubated with antihemagglutinin (HA) (1 : 1000 v/v, Roche Molecular Biochemicals, Mannheim, Germany) followed by horseradish peroxidase-conjugated secondary antibodies and detection by an enhanced chemiluminescence method (ECL, Amersham Pharmacia Biotech, Buckinghamshire, UK). Alternatively, lysates were analysed directly by immunoblotting after normalization for total protein content.
Immunohistochemistry
Antibody for human caspase-8 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1/100) was used to detect caspase-8 protein on the tissue sections. Immunohistochemical procedures were performed as described previously . Tumors were interpreted as positive by immunohistochemistry when at least weak to moderate cytosolic staining was seen in greater than 30% of the neoplastic cells. The results were reviewed independently by two pathologists. As a negative control, a slide was treated by replacement of primary antibody with nonimmune sera.
Abbreviations PCR, polymerase chain reaction; DAPI, 4 0 ,6-diamidine-2 0 -phenylindole dihydrochloride; GFP, green fluorescent protein; SSCP, single-strand conformation polymorphism; LOH, loss of heterozygosity; DISC, death-induced signaling complex; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; FADD, Fas-associated death domain protein; DED, death effector domain; PARP, poly(ADP-ribose) polymerase; Bid, BH3-interacting death agonist; HBV, hepatitis B virus; HCV, hepatitis C virus.
